Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Gilead: Near-Term Drug Filings Planned, But HIV Pressure Persists

This article was originally published in The Pink Sheet Daily

Executive Summary

Gilead expects to file for a new triple combination, Truvada plus Johnson & Johnson's TMC278, later this year, to extend the life of its HIV franchise.

You may also be interested in...



Gilead's Quad Poised To Take Chunk Of Atripla's Market, If Phase III Results Hold Up

Solid efficacy with fewer psych effects than Atripla continue in full-length version of Phase II trials. However, hopes for superior performance have started to wane.

Gilead's Quad Poised To Take Chunk Of Atripla's Market, If Phase III Results Hold Up

Solid efficacy with fewer psych effects than Atripla continue in full-length version of Phase II trials. However, hopes for superior performance have started to wane.

Tibotec Files NNRTI Rilpivirine, Part Of Gilead's New Combo For HIV

Johnson & Johnson subsidiary Tibotec has submitted its once-daily non-nucleoside reverse transcriptase inhibitor TMC278 (rilpivirine) for treatment-naïve HIV patients for FDA approval, close on the heels of releasing pivotal data at the International AIDS Society meeting in Vienna

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS070938

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel